Symbols / RGNX Stock $9.55 +2.25% REGENXBIO Inc.

Healthcare • Biotechnology • United States • NMS
RGNX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Stock Fundamentals
Scroll to Statements
Market Cap 492.94M Enterprise Value 512.51M Income -193.88M Sales 170.44M Book/sh 2.02 Cash/sh 4.46
Dividend Yield — Payout 0.00% Employees 371 IPO — P/E — Forward P/E -4.35
PEG — P/S 2.89 P/B 4.73 P/C — EV/EBITDA -3.52 EV/Sales 3.01
Quick Ratio 2.27 Current Ratio 2.38 Debt/Eq 253.59 LT Debt/Eq — EPS (ttm) -3.76 EPS next Y -2.20
EPS Growth — Revenue Growth 43.00% Earnings 2026-05-11 ROA -21.93% ROE -107.00% ROIC —
Gross Margin -45.86% Oper. Margin -189.99% Profit Margin -113.75% Shs Outstand 51.62M Shs Float 43.00M Short Float 15.72%
Short Ratio 6.91 Short Interest — 52W High 16.19 52W Low 6.89 Beta 1.13 Avg Volume 927.56K
Volume 19.64K Target Price $27.82 Recom Buy Prev Close $9.34 Price $9.55 Change 2.25%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$27.82
Mean price target
2. Current target
$9.55
Latest analyst target
3. DCF / Fair value
$-27.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.55
Low
$12.00
High
$50.00
Mean
$27.82

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-09 main HC Wainwright & Co. Buy → Buy $30
2026-03-06 main Morgan Stanley Overweight → Overweight $17
2026-02-10 main HC Wainwright & Co. Buy → Buy $32
2026-02-10 main Goldman Sachs Neutral → Neutral $12
2026-02-10 main Morgan Stanley Overweight → Overweight $18
2026-02-10 main Chardan Capital Buy → Buy $50
2026-01-29 main Chardan Capital Buy → Buy $52
2025-12-19 main Stifel Buy → Buy $45
2025-12-15 main Leerink Partners Outperform → Outperform $20
2025-11-20 main Chardan Capital Buy → Buy $52
2025-11-07 main RBC Capital Outperform → Outperform $19
2025-10-07 reit HC Wainwright & Co. Buy → Buy $34
2025-09-08 reit HC Wainwright & Co. Buy → Buy $34
2025-09-08 main Chardan Capital Buy → Buy $52
2025-08-19 reit HC Wainwright & Co. Buy → Buy $34
2025-08-08 main RBC Capital Outperform → Outperform $17
2025-08-08 main Barclays Overweight → Overweight $37
2025-08-08 main Chardan Capital Buy → Buy $52
2025-06-09 main Chardan Capital Buy → Buy $52
2025-04-17 main Goldman Sachs Neutral → Neutral $12
News
RSS: Latest RGNX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-10 PAKOLA STEPHEN J Officer — 5,124 $10.35 $53,033
2026-01-27 MILLS KENNETH THOMAS Director — 225,000 $13.09 $2,945,250
2026-01-06 SIMPSON CURRAN M Chief Executive Officer — 144,864 $0.00 $0
2026-01-06 CHRISTMAS PATRICK J. II Officer — 73,749 $0.00 $0
2026-01-06 PAKOLA STEPHEN J Officer — 65,847 $0.00 $0
2026-01-06 CHAN MITCHELL Chief Financial Officer — 73,749 $0.00 $0
2026-01-06 MALZAHN CRAIG Chief Technology Officer — 65,847 $0.00 $0
2025-10-09 SIMPSON CURRAN M Chief Executive Officer — 20,811 $12.62 $262,635
2025-09-29 SIMPSON CURRAN M Chief Executive Officer — 7,624 $10.03 $76,469
2025-09-10 SIMPSON CURRAN M Chief Executive Officer — 7,734 $10.02 $77,495
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
170.44
+104.54%
83.33
-7.66%
90.24
-19.94%
112.72
Operating Revenue
170.44
+104.54%
83.33
-7.66%
90.24
-19.94%
112.72
Cost Of Revenue
20.30
-39.53%
33.57
-9.80%
37.21
-31.78%
54.55
Reconciled Cost Of Revenue
20.30
-39.53%
33.57
-9.80%
37.21
-31.78%
54.55
Gross Profit
150.14
+201.73%
49.76
-6.16%
53.03
-8.85%
58.18
Operating Expense
311.34
+10.80%
281.01
-12.50%
321.16
+0.03%
321.06
Research And Development
228.30
+9.48%
208.52
-10.22%
232.27
-4.20%
242.45
Selling General And Administration
82.86
+8.15%
76.62
-13.42%
88.49
+3.77%
85.28
General And Administrative Expense
82.86
+8.15%
76.62
-13.42%
88.49
+3.77%
85.28
Other Gand A
82.86
+8.15%
76.62
-13.42%
88.49
+3.77%
85.28
Other Operating Expenses
0.18
-79.31%
0.86
+117.88%
0.40
+105.94%
-6.68
Total Expenses
331.64
+5.43%
314.57
-12.22%
358.37
-4.59%
375.60
Operating Income
-161.20
+30.29%
-231.25
+13.76%
-268.13
-2.00%
-262.88
Total Operating Income As Reported
-161.20
+30.92%
-233.35
+12.97%
-268.13
-2.00%
-262.88
EBITDA
-133.25
+32.78%
-198.23
+17.22%
-239.46
+1.96%
-244.24
Normalized EBITDA
-145.50
+32.28%
-214.86
+14.33%
-250.78
-0.46%
-249.62
Reconciled Depreciation
15.62
-3.70%
16.21
-6.38%
17.32
+34.17%
12.91
EBIT
-148.87
+30.58%
-214.44
+16.49%
-256.78
+0.14%
-257.15
Total Unusual Items
12.24
-26.36%
16.63
+46.90%
11.32
+110.27%
5.38
Total Unusual Items Excluding Goodwill
12.24
-26.36%
16.63
+46.90%
11.32
+110.27%
5.38
Special Income Charges
0.00
+100.00%
-2.10
0.00
0.00
Impairment Of Capital Assets
0.00
-100.00%
2.10
0.00
0.00
Net Income
-193.88
+14.63%
-227.10
+13.81%
-263.49
+6.00%
-280.32
Pretax Income
-193.88
+14.63%
-227.10
+13.86%
-263.65
+5.98%
-280.40
Net Non Operating Interest Income Expense
-44.92
-259.83%
-12.48
-82.61%
-6.84
+70.16%
-22.91
Interest Expense Non Operating
45.01
+255.54%
12.66
+84.48%
6.86
-70.49%
23.25
Net Interest Income
-44.92
-259.83%
-12.48
-82.61%
-6.84
+70.16%
-22.91
Interest Expense
45.01
+255.54%
12.66
+84.48%
6.86
-70.49%
23.25
Interest Income Non Operating
0.08
-52.30%
0.17
+596.00%
0.03
-92.69%
0.34
Interest Income
0.08
-52.30%
0.17
+596.00%
0.03
-92.69%
0.34
Other Income Expense
12.24
-26.36%
16.63
+46.90%
11.32
+110.27%
5.38
Gain On Sale Of Security
12.24
-34.62%
18.73
+65.47%
11.32
+110.27%
5.38
Tax Provision
—
0.00
+100.00%
-0.15
-80.95%
-0.08
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
+92.33%
0.00
Tax Effect Of Unusual Items
0.00
0.00
-100.00%
0.01
+304.68%
0.00
Net Income Including Noncontrolling Interests
-193.88
+14.63%
-227.10
+13.81%
-263.49
+6.00%
-280.32
Net Income From Continuing Operation Net Minority Interest
-193.88
+14.63%
-227.10
+13.81%
-263.49
+6.00%
-280.32
Net Income From Continuing And Discontinued Operation
-193.88
+14.63%
-227.10
+13.81%
-263.49
+6.00%
-280.32
Net Income Continuous Operations
-193.88
+14.63%
-227.10
+13.81%
-263.49
+6.00%
-280.32
Normalized Income
-206.12
+15.43%
-243.73
+11.31%
-274.81
+3.81%
-285.70
Net Income Common Stockholders
-193.88
+14.63%
-227.10
+13.81%
-263.49
+6.00%
-280.32
Diluted EPS
—
-4.59
+23.75%
-6.02
+7.38%
-6.50
Basic EPS
—
-4.59
+23.75%
-6.02
+7.38%
-6.50
Basic Average Shares
—
49.51
+13.20%
43.73
+1.35%
43.15
Diluted Average Shares
—
49.51
+13.20%
43.73
+1.35%
43.15
Diluted NI Availto Com Stockholders
-193.88
+14.63%
-227.10
+13.81%
-263.49
+6.00%
-280.32
Provision For Doubtful Accounts
0.00
+100.00%
-5.00
0.00
0.00
Line Item Trend 2023-12-31
Total Assets
573.97
Current Assets
334.97
Cash Cash Equivalents And Short Term Investments
275.26
Cash And Cash Equivalents
34.52
Other Short Term Investments
240.74
Receivables
26.34
Accounts Receivable
4.85
Gross Accounts Receivable
4.85
Allowance For Doubtful Accounts Receivable
-4.59
Receivables Adjustments Allowances
-4.59
Other Receivables
24.52
Accrued Interest Receivable
1.55
Prepaid Assets
14.52
Other Current Assets
18.85
Total Non Current Assets
239.00
Net PPE
192.59
Gross PPE
249.80
Accumulated Depreciation
-57.21
Properties
0.00
Machinery Furniture Equipment
11.75
Other Properties
136.12
Leases
101.93
Investments And Advances
38.87
Non Current Accounts Receivable
0.70
Other Non Current Assets
6.84
Total Liabilities Net Minority Interest
262.23
Current Liabilities
130.27
Payables And Accrued Expenses
54.34
Payables
22.79
Accounts Payable
22.79
Current Accrued Expenses
31.56
Pensionand Other Post Retirement Benefit Plans Current
18.15
Total Tax Payable
—
Income Tax Payable
—
Current Debt And Capital Lease Obligation
7.07
Current Capital Lease Obligation
7.07
Current Deferred Liabilities
0.15
Current Deferred Revenue
0.15
Other Current Liabilities
50.57
Total Non Current Liabilities Net Minority Interest
131.96
Long Term Debt And Capital Lease Obligation
82.22
Long Term Capital Lease Obligation
82.22
Non Current Deferred Liabilities
—
Non Current Deferred Revenue
—
Other Non Current Liabilities
49.73
Stockholders Equity
311.74
Common Stock Equity
311.74
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
44.05
Ordinary Shares Number
44.05
Treasury Shares Number
0.00
Additional Paid In Capital
1,021.21
Retained Earnings
-705.05
Gains Losses Not Affecting Retained Earnings
-4.43
Total Equity Gross Minority Interest
311.74
Total Capitalization
311.74
Working Capital
204.70
Invested Capital
311.74
Total Debt
89.29
Capital Lease Obligations
89.29
Net Tangible Assets
311.74
Tangible Book Value
311.74
Available For Sale Securities
38.87
Investmentin Financial Assets
38.87
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-123.96
+28.40%
-173.12
+20.73%
-218.41
-5.26%
-207.49
Cash Flow From Continuing Operating Activities
-123.96
+28.40%
-173.12
+20.73%
-218.41
-5.26%
-207.49
Net Income From Continuing Operations
-193.88
+14.63%
-227.10
+13.81%
-263.49
+6.00%
-280.32
Depreciation Amortization Depletion
15.62
-3.70%
16.21
-6.38%
17.32
+34.17%
12.91
Depreciation And Amortization
15.62
-3.70%
16.21
-6.38%
17.32
+34.17%
12.91
Other Non Cash Items
13.50
+81.79%
7.42
+7915.79%
-0.10
-125.82%
0.37
Stock Based Compensation
34.56
-10.14%
38.46
-4.48%
40.27
-1.28%
40.79
Provisionand Write Offof Assets
0.00
+100.00%
-5.00
0.00
0.00
Asset Impairment Charge
0.00
-100.00%
2.10
0.00
0.00
Operating Gains Losses
-0.06
+99.06%
-6.62
-200.05%
-2.21
-2891.14%
0.08
Gain Loss On Investment Securities
-0.06
+99.06%
-6.62
-200.05%
-2.21
-2891.14%
0.08
Change In Working Capital
11.78
+112.90%
5.53
+150.82%
-10.89
-177.89%
13.98
Change In Receivables
-7.66
-178.92%
9.71
+146.68%
3.94
-18.39%
4.82
Changes In Account Receivables
-7.66
-178.92%
9.71
+146.68%
3.94
-18.39%
4.82
Change In Prepaid Assets
-2.86
-152.45%
5.45
+979.52%
-0.62
-112.78%
4.85
Change In Payables And Accrued Expense
-2.06
+83.45%
-12.42
-3562.54%
-0.34
+95.03%
-6.83
Change In Accrued Expense
0.23
+101.89%
-12.12
-594.45%
2.45
+109.57%
-25.62
Change In Payable
-2.28
-682.19%
-0.29
+89.54%
-2.79
-114.85%
18.79
Change In Account Payable
-2.28
-682.19%
-0.29
+89.54%
-2.79
-114.85%
18.79
Change In Other Working Capital
29.28
+88827.27%
-0.03
+97.82%
-1.51
-29.79%
-1.17
Change In Other Current Assets
6.70
-50.44%
13.51
+522.97%
-3.19
-167.58%
4.73
Change In Other Current Liabilities
-11.62
-8.70%
-10.69
-16.78%
-9.16
-221.02%
7.57
Investing Cash Flow
-15.87
-115.34%
103.45
-45.82%
190.94
+1700.66%
-11.93
Cash Flow From Continuing Investing Activities
-15.87
-115.34%
103.45
-45.82%
190.94
+1700.66%
-11.93
Net PPE Purchase And Sale
-2.41
+0.90%
-2.44
+75.54%
-9.96
+67.58%
-30.72
Purchase Of PPE
-2.41
+0.90%
-2.44
+75.54%
-9.96
+67.58%
-30.72
Capital Expenditure
-2.41
+0.90%
-2.44
+75.54%
-9.96
+67.58%
-30.72
Net Investment Purchase And Sale
-13.45
-112.71%
105.88
-47.30%
200.90
+968.92%
18.80
Purchase Of Investment
-332.63
-74.94%
-190.14
-119.65%
-86.56
+53.18%
-184.88
Sale Of Investment
319.18
+7.82%
296.02
+2.98%
287.47
+41.14%
203.67
Financing Cash Flow
116.77
+25.99%
92.68
+365.07%
-34.97
-21.24%
-28.84
Cash Flow From Continuing Financing Activities
116.77
+25.99%
92.68
+365.07%
-34.97
-21.24%
-28.84
Net Issuance Payments Of Debt
144.49
0.00
—
—
Issuance Of Debt
144.49
0.00
—
—
Long Term Debt Issuance
144.49
0.00
—
—
Net Long Term Debt Issuance
144.49
0.00
—
—
Net Common Stock Issuance
1.05
-99.21%
132.26
+1874.00%
6.70
+284.62%
1.74
Proceeds From Stock Option Exercised
0.32
-78.97%
1.51
-0.59%
1.52
-45.76%
2.80
Net Other Financing Charges
-29.09
+29.20%
-41.09
+4.86%
-43.19
-29.36%
-33.39
Changes In Cash
-23.06
-200.24%
23.00
+136.85%
-62.43
+74.85%
-248.26
Beginning Cash Position
59.56
+62.93%
36.55
-63.07%
98.98
-71.49%
347.24
End Cash Position
36.50
-38.72%
59.56
+62.93%
36.55
-63.07%
98.98
Free Cash Flow
-126.38
+28.02%
-175.56
+23.12%
-228.37
+4.13%
-238.21
Interest Paid Supplemental Data
32.11
+389.51%
6.56
-9.85%
7.28
-68.53%
23.12
Income Tax Paid Supplemental Data
0.28
—
—
11.81
Amortization Of Securities
-5.48
-32.22%
-4.14
-703.20%
0.69
-85.42%
4.71
Common Stock Issuance
1.05
-99.21%
132.26
+1874.00%
6.70
+284.62%
1.74
Issuance Of Capital Stock
1.05
-99.21%
132.26
+1874.00%
6.70
+284.62%
1.74
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category